Society of Gynecologic Oncology, 2023 Annual Meeting on Women’s Cancer, March 2023
Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer
Immuno-Oncology 360° Conference, February 2023
Delivery Matters: Leveraging the DPX Cancer Vaccine Platform to Educate Sustained Anti-cancer Immunity and Durable Clinical Benefit
San Antony Breast Cancer Symposium (SABCS), December 2022
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC).
RIVKIN - AACR VIRTUAL OVARIAN CANCER RESEARCH SEMINAR SERIES, SEPTEMBER 2022